Antengene to present results from two late-stage studies of selinexor signaling potential clinical breakthrough at ash 2024

Shanghai and hong kong , nov. 5, 2024 /prnewswire/ -- antengene corporation limited ("antengene", sehk: 6996.hk), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present the latest data from two clinical studies of selinexor in two posters at the 2024 american society of hematology annual meeting (ash 2024), taking place on december 7-10, 2024, in san diego, ca, the united states. details on the posters: title: weekly selinexor, bortizomib and dexamethasone (svd) versus twice weekly bortizomib and dexamethasone (vd) in chinese patients with relapsed and refractory multiple myeloma (rrmm): primary analysis of phase iii bench study publication number: 4748 session: 654.
KPTI Ratings Summary
KPTI Quant Ranking